Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
PR

NASDAQ · PRAX

Praxis Precision Medicines, Inc.

Healthcare · Biotechnology

$338.57

Down-$6.73 (-1.95%)

Updated Sep 11, 2026, 7:25 AM

SID Score

5.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap
5.65B
P/E ratio
-22.87
Dividend yield
0.00%
52-week range
$238.77 – $392.70
Volume
218.83K
Avg. volume
1.03M

Price performance

PRAX price history

1M range · 20 trading sessions · Daily adjusted prices

PRAX closed at $338.57 after 20 trading sessions, down 8.11% for the selected period.

Last close
$338.57
Period change
-8.11%
Period low
$338.57
Period high
$386.19
Daily close
View OHLC price history
PRAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$339.60$347.40$337.31$338.57218.83K
Sep 9, 2026$352.80$360.6099$344.03$345.30382.96K
Sep 8, 2026$342.25$356.29$339.50$352.48252.62K
Sep 4, 2026$352.99$357.50$349.8182$351.81175.36K
Sep 3, 2026$355.31$363.14$351.15$355.15200.75K
Sep 2, 2026$358.42$365.71$347.0101$357.50289.4K
Sep 1, 2026$350.00$355.4899$347.86$353.44305.83K
Aug 31, 2026$343.00$351.715$333.46$350.30380.66K
Aug 28, 2026$363.40$367.70$344.69$344.75282.85K
Aug 27, 2026$375.77$377.50$366.875$367.85242.88K
Aug 26, 2026$368.45$383.30$362.79$377.37480.53K
Aug 25, 2026$374.10$382.378$361.985$368.02294.33K
Aug 24, 2026$375.94$375.94$360.19$368.03265.01K
Aug 21, 2026$370.35$387.99$365.37$375.94413.32K
Aug 20, 2026$392.70$392.70$361.1616$364.58496.67K
Aug 19, 2026$377.00$392.45$365.6401$386.19421.8K
Aug 18, 2026$369.40$375.00$365.0501$369.84255.85K
Aug 17, 2026$371.97$391.64$370.03$376.38581.5K
Aug 14, 2026$365.02$368.40$355.1093$366.81262.24K
Aug 13, 2026$388.00$388.00$367.57$368.46274.23K

Latest PRAX news

The latest Smart Investors Daily articles mentioning PRAX.

Stock researchCompany · Overview

PRAX research

Overview

Company profile and research snapshot.

Company profile

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$403.80
Implied upside
—
Analysts
21
PRAX recent ratings
DateFirmRatingTarget
Aug 21, 2026Goldman SachsBuy—
Aug 7, 2026RBC CapitalOutperform—
Aug 7, 2026Wells FargoEqual-Weight—
Aug 6, 2026NeedhamBuy—
Jul 29, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan

Yahoo · Aug 8, 2026

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

Praxis Precision Medicines reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while reaffirming its focus on central nervous system therapies. Alongside widening year-to-date losses, the company highlighted progress on key drug candidates such as ulixacaltamide and relutrigine, supported by a US$1.40 billion cash position that funds operations into 2028. With this mix of heavier losses and robust...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By